DPC 168

Drug Profile

DPC 168

Latest Information Update: 03 Sep 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antiallergics; Antiasthmatics; Phenylurea compounds
  • Mechanism of Action CCR3 receptor antagonists; Chemokine CCL11 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Allergic rhinitis; Asthma

Most Recent Events

  • 23 May 2007 Discontinued - Phase-I for Allergic rhinitis in USA (unspecified route)
  • 23 May 2007 Discontinued - Phase-I for Asthma in USA (unspecified route)
  • 19 Mar 2001 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top